Therapeutic drug monitoring of amikacin in septic patients

Clicks: 291
ID: 267481
2013
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
TDM resulted in adjustment of AMK therapy in most of our septic patients. Early achievement of an optimal Cpeak/MIC ratio may have an impact on clinical and microbiological responses, but not on outcome. In patients with impaired renal function prior to treatment, AMK therapy may be associated with …
Reference Key
w2013criticaltherapeutic Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Duszynska W;Taccone FS;Hurkacz M;Kowalska-Krochmal B;Wiela-Hojeńska A;Kübler A;;
Journal critical care (london, england)
Year 2013
DOI
DOI not found
URL
https://www.ncbi.nlm.nih.gov/pubmed/23886243
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine adult female male aged middle aged sepsis / drug therapy* dose-response relationship drug anti-bacterial agents / therapeutic use* amikacin / therapeutic use* anti-bacterial agents / blood pmid:23886243 pmc4057344 doi:10.1186/cc12844 wieslawa duszynska fabio silvio taccone andrzej kübler amikacin / blood critical illness / therapy* drug monitoring / methods* metabolic clearance rate / physiology sepsis / blood sepsis / diagnosis

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.